Recombinant Anti-albumin x Anti-IL-6R Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-albumin antibody variable domain is fused to CH1 and the other scFv from an anti-IL-6R antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can act as PK-modulated receptor antagonist. It is designed for the research of Lupus, rheumatoid arthritis therapy.